Should we pay more to treat rare diseases?

rare-disease-large-1-

The UK’s public health watchdog is pressing ahead with plans to introduce a “dynamic upper limit” to the price new orphan drugs recommended for use in the National Health Service (NHS) can command.

The approach will introduce “a sliding scale, so that the more the medicine costs the greater the health benefit it must provide in order to be approved for routine use.”

The upper limit for orphan drugs will be £300,000 ($370,000) per quality-adjusted life year, triple the amount originally proposed by the National Institute for Health and Care Excellence (NICE).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical